August 30, 2012—Health Resources and Services Administration (HRSA) program integrity audits of two hospitals' 340B drug discount programs identified no occurrences of drug diversion to ineligible patients, duplicate discounts under Medicaid, or eligibility issues, the Drug Discount Monitor has learned. Denver Health and Hospital Authority, an integrated public health system … [Read more...]
“C-suite” Executives Share Lessons About 340B
Webinar focuses on benefits to patients and compliance best practicesAugust 28, 2012—Without 340B drug discounts, safety-net hospitals and community health centers (CHCs) would find it difficult, if not impossible, to continue providing free or reduced-cost comprehensive pharmacy care to the poor and uninsured, top senior executives at six 340B hospitals and centers said during a recent Pharmacy Services Support Center (PSSC) webinar. But … [Read more...]
340B Health Center Recertification Set to Begin in January
New patient eligibility guidance coming "in the near future," Pedley says during webinarAugust 16, 2012—The Office of Pharmacy Affairs (OPA) plans to begin recertifying federally qualified health centers (FQHCs) enrolled in the 340B program in January, with the first notification emails being sent to centers' authorizing officials in November, OPA announced this week. During an Aug. 14 webinar, OPA Director Cmdr. Krista Pedley also said that 340B stakeholders … [Read more...]
OPA Moving 340B Change Request Process Online
Paper forms will still be required for termination requests and some other updatesAugust 8, 2012—Beginning next week, health care providers that need to update certain information in the Office of Pharmacy Affairs' (OPA) 340B covered entity database will have to use a new online tool instead of submitting paper forms. OPA made the announcement on its home page this morning. … [Read more...]
OPA No Longer Posting 340B Hospital DSH Data on Its Web Site
Says it is assessing alternatives to list that came from CMSAugust 3, 2012—The Office of Pharmacy Affairs (OPA) is no longer relying on disproportionate share (DSH) adjustment percentage data from the Centers for Medicare and Medicaid Services (CMS) to assist in the determination of whether a hospital qualifies for 340B, and it will not be posting DSH payment percentages on its Web site any longer. The following announcement recently … [Read more...]
CMS Issues Medicare Hospital Outpatient Payment Proposal for 2013
Says it intends to pay ASP + 6% for separately payable drugs and biologicalsAugust 1, 2012—The Centers for Medicare and Medicaid Services (CMS) has proposed to budget $48.1 billion for Medicare reimbursement to hospital outpatient facilities in 2013, an increase of 2.1 percent above this year’s level. In addition, it will increase the payment rate for separately payable drugs and biologicals by 2 percent and drop a problematic payment methodology that … [Read more...]
Octapharma Partners With Apexus to Provide IGIV at Sub-340B Price
Sub-ceiling price available for octagam 5% now and possibly for 10% formulation laterAugust 1, 2012—Octapharma USA's octagam 5% immune globulin intravenous (IGIV) therapy is now available at sub-340B pricing to participants in the Apexus/340B Prime Vendor Program (PVP). Apexus Director of Contract Services John Barnes made the announcement in a July 30 email to PVP participants. … [Read more...]